{"id":"NCT04322708","sponsor":"Allakos Inc.","briefTitle":"A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis","officialTitle":"A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-07-06","primaryCompletion":"2021-06-04","completion":"2022-01-18","firstPosted":"2020-03-26","resultsPosted":"2024-01-02","lastUpdate":"2024-01-02"},"enrollment":277,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Esophagitis"],"interventions":[{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"lirentelimab (AK002)","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"1 mg/kg of lirentelimab (AK002)","type":"EXPERIMENTAL"},{"label":"3 mg/kg of lirentelimab (AK002)","type":"EXPERIMENTAL"}],"summary":"This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic esophagitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.","primaryOutcome":{"measure":"Proportion of Subjects Who Achieve a Peak Esophageal Intraepithelial Count of â‰¤6 Eosinophils/Hpf at Week 24","timeFrame":"At Week 24","effectByArm":[{"arm":"1 mg/kg of Lirentelimab (AK002)","deltaMin":86,"sd":null},{"arm":"3 mg/kg of Lirentelimab (AK002)","deltaMin":80,"sd":null},{"arm":"Placebo","deltaMin":10,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":78,"countries":["United States","Australia","Netherlands"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":93},"commonTop":["Infusion related reaction","Headache","Nausea","Vomiting","Fatigue"]}}